A biodegradable‐polymer sirolimus‐eluting stent (BP-SES) with an ultra-thin strut, known Supraflex Cruz, was noninferior for target lesion failure (TLF) compared to the widely-used permanent everolimus-eluting stent (EES) Xience in diabetic patients with multi-vessel disease (MVD) at 1 year, India’s TUXEDO-2 randomized trial found.